Suchergebnisse - "Laharie, David"

PubPharm (22)

1

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis : QUASAR Phase 2b Induction Study

enthalten in: Gastroenterology | 2023

von Peyrin-Biroulet, L. | Allegretti, J. | Rubin, D. | +115

2

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease

enthalten in: United European gastroenterology journal | 2021

von Buisson, A. | Nancey, S. | Manlay, L. | +11

3

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients : a multicentre cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2021

von Wils, P. | Seksik, P. | Stefanescu, C. | +68

CommentIn: Aliment Pharmacol Ther. 2021 Feb;53(3):450-451. - PMID 33428251

4

Editorial : biologics in the therapy of Crohn's disease-the fog clears

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Laharie, D. | Riviere, P.

CommentOn: Aliment Pharmacol Ther. 2020 Aug;52(4):669-681. - PMID 32656800

5

Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation : A Multicentre Cohort Study

enthalten in: Journal of Crohn's & colitis | 2020

von Martin, A. | Nachury, M. | Peyrin-Biroulet, L. | +62

6

Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent : a multicentre cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Hupé, M. | Rivière, P. | Nancey, S. | +11

CommentIn: Aliment Pharmacol Ther. 2020 Jun;51(11):1198-1199. - PMID 32424929

7

Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2020

von Lair-Mehiri, L. | Stefanescu, C. | Vaysse, T. | +15

8

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Dulai, P. | Amiot, A. | Peyrin-Biroulet, L. | +95

CommentIn: Aliment Pharmacol Ther. 2020 Apr;51(7):738-739. - PMID 32162371

9

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease : A GETAID Multicentre Cohort Study

enthalten in: Journal of Crohn's & colitis | 2019

von Caron, B. | Peyrin-Biroulet, L. | Pariente, B. | +21

CommentIn: J Crohns Colitis. 2019 Sep 27;13(10):1237-1238. - PMID 31560065

10

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

enthalten in: The New England journal of medicine | 2019

von Sands, B. | Peyrin-Biroulet, L. | Loftus, E. | +111

CommentIn: N Engl J Med. 2019 Sep 26;381(13):1279-1281. - PMID 31553842